Pipeline Overview
Pipeline Overview
About Us
Osteal Therapeutics is a privately-held, clinical-stage pharmaceutical company developing novel musculoskeletal therapeutics to treat orthopedic infections and their consequences.
The lead product under development, NEXCHANGE™ KIT (formerly known as VT-X7), is a drug-device combination product designed for local antibiotic delivery to treat infected joint prosthesis. If granted FDA approval, NEXCHANGE KIT would become the first therapy specifically indicated for the treatment of periprosthetic joint infection (PJI). NEXCHANGE KIT has undergone extensive pre-clinical development and completed two Phase 2 clinical trials where all primary endpoints were successfully met.
Osteal Therapeutics employs a low risk development strategy by improving delivery of pharmaceuticals with long histories of safety and efficacy.
The company is lead by a highly experienced team of orthopedic industry veterans supported by world-class clinical partners.